Index - P/E - EPS (ttm) -2.28 Insider Own 0.90% Shs Outstand 58.75M Perf Week 4.76%
Market Cap 2.11B Forward P/E - EPS next Y -2.98 Insider Trans -26.24% Shs Float 49.26M Perf Month 40.96%
Income -120.30M PEG - EPS next Q -0.61 Inst Own 87.40% Short Float 26.17% Perf Quarter 75.18%
Sales 62.30M P/S 33.92 EPS this Y -6.30% Inst Trans 5.96% Short Ratio 13.26 Perf Half Y 104.80%
Book/sh 5.61 P/B 6.39 EPS next Y -29.00% ROA -30.10% Target Price 35.96 Perf Year 115.25%
Cash/sh 6.92 P/C 5.18 EPS next 5Y 30.00% ROE -40.10% 52W Range 9.18 - 35.54 Perf YTD 144.44%
Dividend - P/FCF - EPS past 5Y -50.60% ROI - 52W High 0.90% Beta 1.74
Dividend % - Quick Ratio 7.50 Sales past 5Y - Gross Margin - 52W Low 290.63% ATR 1.90
Employees 270 Current Ratio 7.50 Sales Q/Q 109.40% Oper. Margin - RSI (14) 72.83 Volatility 5.71% 6.50%
Optionable Yes Debt/Eq 0.00 EPS Q/Q 2.70% Profit Margin - Rel Volume 0.83 Prev Close 34.81
Shortable Yes LT Debt/Eq 0.00 Earnings Nov 05 BMO Payout - Avg Volume 971.95K Price 35.86
Recom 2.10 SMA20 20.64% SMA50 39.56% SMA200 84.44% Volume 804,001 Change 3.02%
Oct-27-20 Initiated Truist
Buy
$40
Oct-14-20 Initiated Wells Fargo
Overweight
Sep-18-20 Initiated Goldman
Buy
$33
Feb-28-20 Upgrade Oppenheimer
Perform → Outperform
Feb-14-20 Downgrade Wedbush
Outperform → Neutral
$16
Nov-01-19 Upgrade Raymond James
Mkt Perform → Outperform
Jul-09-19 Initiated Robert W. Baird
Outperform
$23
Jun-10-19 Initiated ROTH Capital
Neutral
$16
May-03-19 Upgrade Wedbush
Neutral → Outperform
$20 → $21
Apr-12-19 Initiated Evercore ISI
Outperform
Nov-02-18 Downgrade Wedbush
Outperform → Neutral
$36 → $20
Oct-29-18 Initiated Credit Suisse
Neutral
$24
Sep-21-18 Initiated Raymond James
Mkt Perform
May-15-18 Upgrade Chardan Capital Markets
Neutral → Buy
$20 → $57.50
Mar-08-18 Initiated JMP Securities
Mkt Outperform
$76
Nov-01-17 Reiterated Jefferies
Buy
$36 → $42
Jun-22-17 Resumed Jefferies
Buy
$36
Mar-28-17 Initiated Chardan Capital Markets
Buy
$19
Aug-05-16 Upgrade Jefferies
Hold → Buy
May-31-16 Initiated Wedbush
Outperform
$38
Nov-11-20 07:30AM Nov-09-20 07:30AM 05:57AM Nov-06-20 05:30PM Nov-05-20 07:30AM 06:15AM Oct-29-20 07:30AM Oct-27-20 10:35AM Oct-19-20 07:30AM Oct-07-20 04:20PM 10:04AM Oct-05-20 07:30AM Sep-29-20 08:20AM Sep-28-20 08:00AM Sep-22-20 09:43AM Sep-18-20 09:31AM Sep-02-20 08:00AM Aug-11-20 11:10AM 11:06AM Aug-06-20 09:15AM 07:30AM Aug-03-20 08:00AM Jul-30-20 12:33PM 07:30AM Jul-25-20 11:52AM Jul-14-20 07:07AM Jul-05-20 10:52PM Jul-02-20 11:32AM Jun-10-20 11:48PM Thomson Reuters StreetEvents
Jun-05-20 04:01PM 12:37AM Jun-03-20 09:56AM 07:54AM 07:02AM Jun-02-20 09:00PM 11:09AM 09:15AM 07:45AM 02:35AM Jun-01-20 04:00PM 11:46AM 07:57AM 07:00AM May-22-20 07:39AM May-18-20 07:12PM Investor's Business Daily +5.89%
May-12-20 06:00AM May-11-20 07:43AM May-09-20 01:31PM May-07-20 09:15AM 08:38AM 07:30AM Apr-30-20 12:34PM 07:50AM 07:30AM Apr-28-20 04:30PM Apr-13-20 12:00PM Apr-06-20 06:26PM Mar-31-20 07:30AM Mar-24-20 04:19PM Thomson Reuters StreetEvents
Feb-27-20 08:55AM 07:30AM Feb-20-20 10:53AM 07:30AM Feb-19-20 12:31PM Feb-12-20 09:33AM Feb-10-20 07:30AM Feb-07-20 08:54AM Jan-17-20 02:09PM American City Business Journals
Jan-09-20 07:30AM Jan-06-20 11:00PM Dec-30-19 04:07PM Investor's Business Daily
03:40PM Dec-25-19 11:30AM Dec-17-19 06:00AM American City Business Journals
Dec-14-19 09:13PM Dec-10-19 10:38AM Dec-05-19 03:49AM Dec-04-19 09:42AM Dec-03-19 01:03AM Dec-02-19 06:33AM American City Business Journals
Nov-26-19 08:00AM Nov-20-19 03:11PM Thomson Reuters StreetEvents
09:12AM 01:05AM Nov-19-19 10:46AM American City Business Journals +10.15%
09:40AM Nov-13-19 01:01AM Nov-07-19 09:44AM 06:08AM American City Business Journals
Oct-31-19 09:15AM 07:30AM 04:30AM Oct-30-19 08:34PM Oct-29-19 04:05PM Oct-24-19 08:00AM 07:30AM Oct-23-19 10:33AM Oct-16-19 08:00AM Oct-07-19 06:00AM American City Business Journals
Sep-30-19 08:00AM
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; Ospedale San Raffaele; and GEMoaB Monoconals GmbH. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
LEONARD JOHN M President and CEO Nov 25 Option Exercise 6.83 50,000 341,500 517,352 Nov 25 08:02 PM LEONARD JOHN M President and CEO Nov 25 Sale 36.00 50,000 1,800,000 467,352 Nov 25 08:02 PM Rivera Jose E EVP, General Counsel Nov 18 Option Exercise 18.30 848 15,518 47,696 Nov 18 07:55 PM Rivera Jose E EVP, General Counsel Nov 18 Sale 35.00 624 21,840 47,072 Nov 18 07:55 PM Rivera Jose E EVP, General Counsel Nov 16 Option Exercise 7.44 10,562 78,585 52,315 Nov 18 07:55 PM LEONARD JOHN M President and CEO Nov 16 Option Exercise 14.58 20,000 291,600 487,352 Nov 18 07:56 PM LEONARD JOHN M President and CEO Nov 16 Sale 34.00 20,000 680,000 467,352 Nov 18 07:56 PM Rivera Jose E EVP, General Counsel Nov 16 Sale 34.29 6,029 206,728 46,700 Nov 18 07:55 PM LEONARD JOHN M President and CEO Nov 04 Option Exercise 6.83 50,000 341,500 517,352 Nov 06 04:38 PM Rivera Jose E EVP, General Counsel Nov 04 Option Exercise 13.88 5,000 69,400 45,679 Nov 06 04:41 PM LEONARD JOHN M President and CEO Nov 04 Sale 26.00 50,000 1,300,000 467,352 Nov 06 04:38 PM Rivera Jose E EVP, General Counsel Nov 04 Sale 28.00 3,364 94,192 42,315 Nov 06 04:41 PM Rivera Jose E EVP, General Counsel Oct 15 Option Exercise 6.83 10,000 68,300 46,294 Oct 16 08:58 PM Rivera Jose E EVP, General Counsel Oct 15 Sale 24.20 5,615 135,883 40,679 Oct 16 08:58 PM LEONARD JOHN M President and CEO Oct 07 Option Exercise 6.83 5,000 34,150 472,352 Oct 09 04:14 PM LEONARD JOHN M President and CEO Oct 07 Sale 21.83 5,000 109,150 467,352 Oct 09 04:14 PM Rivera Jose E EVP, General Counsel Sep 15 Option Exercise 6.83 10,000 68,300 41,909 Sep 17 04:55 PM Rivera Jose E EVP, General Counsel Sep 15 Sale 21.04 5,615 118,140 36,294 Sep 17 04:55 PM LEONARD JOHN M. President and CEO Sep 01 Option Exercise 6.83 5,000 34,150 472,352 Sep 03 04:15 PM LEONARD JOHN M. President and CEO Sep 01 Sale 21.83 5,000 109,150 467,352 Sep 03 04:15 PM Rivera Jose E EVP, General Counsel Aug 18 Option Exercise 6.83 10,000 68,300 37,524 Aug 20 04:13 PM Rivera Jose E EVP, General Counsel Aug 18 Sale 21.00 5,615 117,915 31,909 Aug 20 04:13 PM LEONARD JOHN M. President and CEO Aug 06 Option Exercise 6.83 5,000 34,150 472,352 Aug 07 07:29 PM LEONARD JOHN M. President and CEO Aug 06 Sale 21.83 5,000 109,150 467,352 Aug 07 07:29 PM Rivera Jose E EVP, General Counsel Jul 15 Option Exercise 6.83 10,000 68,300 33,139 Jul 17 04:18 PM Rivera Jose E EVP, General Counsel Jul 15 Sale 22.70 5,615 127,461 27,524 Jul 17 04:18 PM LEONARD JOHN M. President and CEO Jul 01 Option Exercise 6.83 5,000 34,150 472,352 Jul 02 04:10 PM LEONARD JOHN M. President and CEO Jul 01 Sale 21.83 5,000 109,150 467,352 Jul 02 04:10 PM Rivera Jose E EVP, General Counsel Jun 16 Option Exercise 6.83 10,000 68,300 27,897 Jun 18 05:00 PM Rivera Jose E EVP, General Counsel Jun 16 Sale 21.00 5,615 117,915 22,282 Jun 18 05:00 PM LEONARD JOHN M. President and CEO Jun 03 Option Exercise 6.83 5,000 34,150 472,352 Jun 05 05:18 PM LEONARD JOHN M. President and CEO Jun 03 Sale 21.83 5,000 109,150 467,352 Jun 05 05:18 PM Rivera Jose E EVP, General Counsel May 26 Option Exercise 6.83 10,000 68,300 285,722 May 28 05:23 PM Rivera Jose E EVP, General Counsel May 26 Sale 21.21 5,615 119,094 280,107 May 28 05:23 PM
Index S&P 500 P/E 189.16 EPS (ttm) 0.90 Insider Own 0.40% Shs Outstand 191.30M Perf Week 0.47%
Market Cap 32.53B Forward P/E 21.63 EPS next Y 7.85 Insider Trans -81.59% Shs Float 189.65M Perf Month 6.74%
Income 176.00M PEG 14.08 EPS next Q 2.01 Inst Own 91.80% Short Float 1.00% Perf Quarter 7.17%
Sales 10.96B P/S 2.97 EPS this Y -11.10% Inst Trans -0.53% Short Ratio 1.91 Perf Half Y 13.61%
Book/sh 30.56 P/B 5.56 EPS next Y 24.15% ROA 0.80% Target Price 198.89 Perf Year 14.81%
Cash/sh 8.06 P/C 21.08 EPS next 5Y 13.44% ROE 3.10% 52W Range 81.79 - 180.77 Perf YTD 9.94%
Dividend - P/FCF 26.77 EPS past 5Y -18.80% ROI 3.60% 52W High -6.03% Beta 1.42
Dividend % - Quick Ratio 1.10 Sales past 5Y 15.20% Gross Margin 34.00% 52W Low 107.69% ATR 4.69
Employees 67000 Current Ratio 1.10 Sales Q/Q 0.60% Oper. Margin 5.40% RSI (14) 55.07 Volatility 1.61% 2.69%
Optionable Yes Debt/Eq 2.13 EPS Q/Q 81.00% Profit Margin 1.60% Rel Volume 0.82 Prev Close 172.00
Shortable Yes LT Debt/Eq 2.11 Earnings Oct 20 BMO Payout 0.00% Avg Volume 992.69K Price 169.87
Recom 1.80 SMA20 1.72% SMA50 3.99% SMA200 15.34% Volume 817,074 Change -1.24%
Jul-07-20 Initiated Stephens
Equal-Weight
$150
Mar-02-20 Initiated Deutsche Bank
Buy
$190
Jan-08-20 Initiated Wells Fargo
Overweight
$180
Jan-07-20 Initiated Citigroup
Buy
$185
Dec-13-19 Upgrade CFRA
Sell → Hold
Nov-14-19 Upgrade Wolfe Research
Peer Perform → Outperform
Jun-21-19 Upgrade Mizuho
Neutral → Buy
$150 → $175
May-28-19 Initiated SVB Leerink
Outperform
Jan-18-19 Upgrade Jefferies
Hold → Buy
Oct-09-18 Initiated UBS
Buy
Oct-02-18 Reiterated Robert W. Baird
Outperform
$143 → $146
Jul-25-18 Upgrade BofA/Merrill
Neutral → Buy
Jul-25-18 Reiterated Stifel
Buy
$128 → $150
Jul-03-18 Upgrade Raymond James
Outperform → Strong Buy
Apr-13-18 Upgrade Goldman
Neutral → Buy
Mar-07-18 Upgrade SunTrust
Hold → Buy
Jan-19-18 Initiated Evercore ISI
Outperform
$112
Nov-19-20 11:30AM Nov-10-20 09:43AM Nov-05-20 09:35AM 09:32AM Nov-02-20 08:00AM Oct-23-20 09:35AM Oct-20-20 03:00PM 01:27PM 10:58AM 08:25AM 07:16AM 07:00AM Oct-19-20 10:14AM 08:34AM Oct-15-20 10:00AM Oct-13-20 12:30PM 08:58AM Oct-12-20 08:00AM Oct-07-20 04:15PM Oct-06-20 08:00AM Sep-23-20 09:46AM Sep-14-20 08:10AM Aug-31-20 01:45PM 08:58AM Aug-26-20 02:59PM Aug-21-20 11:30AM 10:54AM Aug-08-20 03:04PM Aug-05-20 08:00AM Aug-04-20 08:00AM Jul-31-20 11:09AM Jul-30-20 11:40AM Jul-29-20 08:00AM Jul-25-20 10:39AM Jul-23-20 08:00AM Jul-22-20 01:00PM 10:18AM 10:09AM 08:25AM 07:58AM 07:30AM 07:00AM Jul-21-20 06:12PM 06:00PM 06:00PM Jul-20-20 08:01AM Jul-17-20 11:27AM Jul-15-20 12:31PM Jul-14-20 11:07AM 08:00AM Jul-08-20 04:15PM 03:22PM Jul-02-20 08:00AM Jun-23-20 06:14PM Jun-09-20 09:24AM Jun-03-20 08:00AM Jun-02-20 10:58AM Jun-01-20 10:07AM May-28-20 01:18PM 11:31AM May-27-20 07:14PM May-26-20 03:54PM May-21-20 08:00AM May-20-20 08:00AM May-11-20 10:08AM May-07-20 11:52AM May-01-20 08:36AM Apr-29-20 09:20AM Apr-28-20 06:01PM 12:07PM 11:01AM 09:27AM 08:25AM 07:00AM Apr-27-20 09:43AM 07:03AM Apr-24-20 12:28PM Apr-23-20 05:49AM Apr-22-20 03:04PM Apr-07-20 09:28AM Apr-06-20 07:00PM Apr-03-20 03:00PM American City Business Journals
10:11AM 07:02AM Apr-02-20 08:29PM 02:54PM American City Business Journals
Mar-26-20 01:15PM Mar-24-20 08:00AM Mar-13-20 11:30AM Mar-12-20 12:41PM Mar-09-20 03:34PM Mar-07-20 10:31AM 10:10AM Feb-24-20 02:59PM American City Business Journals
Feb-20-20 08:49AM Feb-19-20 06:56AM American City Business Journals
06:23AM Feb-17-20 06:31PM Thomson Reuters StreetEvents
05:21AM Feb-13-20 04:41PM
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company has a strategic alliance with ACCORD-2 to provide single research platform to speed development of new COVID-19 treatments. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Rittenmeyer Ronald A Director Nov 24 Sale 172.96 9,590 1,658,686 11,894 Nov 25 05:03 PM Rittenmeyer Ronald A Director Nov 16 Sale 174.35 40,792 7,112,085 21,484 Nov 18 05:03 PM BOUSBIB ARI See Remarks Oct 12 Sale 170.00 69,120 11,750,400 652,035 Oct 14 05:05 PM BOUSBIB ARI See Remarks Sep 15 Sale 164.36 46,080 7,573,709 652,035 Sep 17 05:06 PM BOUSBIB ARI See Remarks Aug 14 Sale 161.66 69,120 11,173,939 652,035 Aug 18 05:03 PM STAUB W RICHARD See Remarks Aug 07 Option Exercise 87.20 33,890 2,955,127 32,877 Aug 11 05:02 PM STAUB W RICHARD See Remarks Aug 07 Sale 160.32 20,367 3,265,332 12,470 Aug 11 05:02 PM Bruehlman Ronald E See Remarks Aug 04 Buy 159.94 10,000 1,599,400 26,751 Aug 05 05:02 PM TPG Group Holdings (SBS) Advis Former Director Jul 28 Sale 159.12 2,919,051 464,479,395 0 Jul 29 04:42 PM BOUSBIB ARI See Remarks Jul 22 Sale 160.00 46,080 7,372,800 652,035 Jul 24 05:09 PM BOUSBIB ARI See Remarks Jun 02 Sale 150.11 164,877 24,749,686 652,035 Jun 04 05:35 PM BOUSBIB ARI See Remarks Jun 01 Sale 150.00 19,443 2,916,450 652,035 Jun 03 05:35 PM EVANISKO MICHAEL J Director Mar 24 Option Exercise 21.20 6,600 139,920 11,850 Mar 26 05:00 PM Knightly Kevin C See Remarks Feb 21 Sale 163.43 2,191 358,075 0 Feb 25 05:02 PM Knightly Kevin C See Remarks Feb 19 Sale 165.09 5,688 939,032 2,191 Feb 20 05:03 PM STAUB W RICHARD See Remarks Feb 18 Option Exercise 78.21 18,224 1,425,299 35,953 Feb 20 05:05 PM STAUB W RICHARD See Remarks Feb 18 Sale 163.77 14,550 2,382,854 21,403 Feb 20 05:05 PM TPG Group Holdings (SBS) Advis Director Feb 13 Sale 164.30 2,996,172 492,271,060 2,919,051 Feb 18 07:00 PM CONNAUGHTON JOHN Director Feb 13 Sale 164.30 703,828 115,638,940 685,712 Feb 18 04:29 PM EVANISKO MICHAEL J Director Jan 31 Option Exercise 23.70 6,250 148,125 11,500 Feb 04 05:02 PM EVANISKO MICHAEL J Director Jan 31 Sale 155.19 6,250 969,938 5,250 Feb 04 05:02 PM EVANISKO MICHAEL J Director Jan 24 Option Exercise 20.31 6,250 126,925 11,500 Jan 28 05:00 PM EVANISKO MICHAEL J Director Jan 24 Sale 159.07 6,250 994,188 5,250 Jan 28 05:00 PM EVANISKO MICHAEL J Director Jan 17 Option Exercise 18.40 6,250 115,000 11,500 Jan 21 05:00 PM EVANISKO MICHAEL J Director Jan 17 Sale 160.76 6,250 1,004,750 5,250 Jan 21 05:00 PM EVANISKO MICHAEL J Director Jan 10 Option Exercise 18.40 6,250 115,000 11,500 Jan 14 04:56 PM EVANISKO MICHAEL J Director Jan 10 Sale 160.08 6,250 1,000,500 5,250 Jan 14 04:56 PM MCDONNELL MICHAEL R EVP and CFO Jan 02 Sale 155.07 12,000 1,860,840 14,366 Jan 06 05:05 PM LEONARD JOHN M. Director Dec 20 Option Exercise 64.77 20,200 1,308,254 28,452 Dec 26 04:33 PM LEONARD JOHN M. Director Dec 20 Sale 153.00 20,200 3,090,600 8,252 Dec 26 04:33 PM
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
